Año 2017
Autores PH Research - Más
Registro de estudios EU Clinical Trials Register
Mostrar resumen Esconder resumen

Este artículo no tiene resumen

Mostrar resumen Esconder resumen
Año 2018
Registro de estudios EU Clinical Trials Register
Mostrar resumen Esconder resumen

Este artículo no tiene resumen

Mostrar resumen Esconder resumen
Año 2018
Autores Dong-A University Hospital - Más
Registro de estudios clinicaltrials.gov
Mostrar resumen Esconder resumen

To investigate the efficacy of Avelumab when given in combination with paclitaxel as a first line treatment for the patients with inoperable angiosarcoma.

Mostrar resumen Esconder resumen
Año 2017
Registro de estudios clinicaltrials.gov
Mostrar resumen Esconder resumen

This is a single-center, single-arm, open-label, pilot trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 3, poorly-differentiated neuroendocrine.carcinoma.

Mostrar resumen Esconder resumen
Año 2018
Autores Dana-Farber Cancer Institute - Más
Registro de estudios clinicaltrials.gov
Mostrar resumen Esconder resumen

This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)

Mostrar resumen Esconder resumen
Año 2017
Registro de estudios clinicaltrials.gov
Mostrar resumen Esconder resumen

This is an open-label phase IB trial with Bioimmunoradiotherapy, i.e. concurrent radiotherapy with intravenous administration of cetuximab and avelumab followed by avelumab maintenance therapy in patients with locally advanced head and neck cancer, unfit for cisplatin.

Mostrar resumen Esconder resumen
Año 2017
Registro de estudios clinicaltrials.gov
Mostrar resumen Esconder resumen

This is a single-center, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.

Mostrar resumen Esconder resumen
Año 2018
Autores EMD Serono - Más
Registro de estudios clinicaltrials.gov
Mostrar resumen Esconder resumen

The main purpose of the study is to evaluate a safe, tolerable recommended Phase II dose (RP2D) and/or the maximum tolerated dose (MTD) of M3814 when given in combination with avelumab with and without radiotherapy in participants with selected advanced solid tumors.

Mostrar resumen Esconder resumen
Año 2019
Autores EMD Serono - Más
Registro de estudios clinicaltrials.gov
Mostrar resumen Esconder resumen

The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.

Mostrar resumen Esconder resumen
Año 2018
Registro de estudios clinicaltrials.gov
Mostrar resumen Esconder resumen

To determine the feasibility and safety of avelumab and gemcitabine combination therapy in patients with metastatic sRCC.

Mostrar resumen Esconder resumen